Supriya Lifescience Limited

We are one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. As of March 31, 2021, we have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. We have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively, of the API exports from India, between Fiscal 2017 and 2020. We were among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume (Source: CRISIL Report).

IPO Timeline:

Date of filing17 May 2021
IPO OpenYet to be declared
IPO closeYet to be declared
Allotment DateYet to be declared
Initiation of RefundsYet to be declared
Credit of shares in DematYet to be declared
Listing on exchangeYet to be declared

Issue Details:

ExchangeBSE, NSE
Issue Type
Face Value
Price Band
Lot Size
Issue Size
Offer for Sale
Fresh Issue

Subscription Quota:

CategoryQuota
QIB
NII
RII
Total

Subscription Status:

CategorySubscription
QIB
NII
RII
Total

Profit & Loss Statement (₹ in Cr) :

31 Dec 2020
(nine month)
31 March 202031 March 201931 March 2018
Total Revenue268323286222
Total Expense153213213191
Profit after Tax76.073.239.38.72

Other Financials (₹ in Cr) :

31 Dec 202031 March 202031 March 201931 March 2018
Total Equity2251499455
Total Liability131187159191
Debt to equity0.581.251.693.47

Leave a Reply

Your email address will not be published. Required fields are marked *